Insulet Corp
NASDAQ:PODD

Watchlist Manager
Insulet Corp Logo
Insulet Corp
NASDAQ:PODD
Watchlist
Price: 273.1 USD 2.51%
Market Cap: 19.1B USD
Have any thoughts about
Insulet Corp?
Write Note

Insulet Corp
Accrued Liabilities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Insulet Corp
Accrued Liabilities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Accrued Liabilities CAGR 3Y CAGR 5Y CAGR 10Y
Insulet Corp
NASDAQ:PODD
Accrued Liabilities
$423.9m
CAGR 3-Years
46%
CAGR 5-Years
36%
CAGR 10-Years
33%
Becton Dickinson and Co
NYSE:BDX
Accrued Liabilities
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Boston Scientific Corp
NYSE:BSX
Accrued Liabilities
$2.3B
CAGR 3-Years
4%
CAGR 5-Years
7%
CAGR 10-Years
7%
Stryker Corp
NYSE:SYK
Accrued Liabilities
$3.5B
CAGR 3-Years
6%
CAGR 5-Years
7%
CAGR 10-Years
3%
Abbott Laboratories
NYSE:ABT
Accrued Liabilities
$6.5B
CAGR 3-Years
-1%
CAGR 5-Years
4%
CAGR 10-Years
6%
Intuitive Surgical Inc
NASDAQ:ISRG
Accrued Liabilities
$867.5m
CAGR 3-Years
21%
CAGR 5-Years
13%
CAGR 10-Years
15%
No Stocks Found

Insulet Corp
Glance View

Market Cap
19.2B USD
Industry
Health Care

Insulet Corporation is a pioneering medical device company, primarily recognized for its innovative Omnipod Insulin Management System, which revolutionizes diabetes care. Founded in 2000, Insulet has focused on developing patch pump technology that offers a seamless, tubeless insulin delivery solution for individuals with insulin-dependent diabetes. This cutting-edge product allows users to manage their insulin delivery discreetly and conveniently, enhancing their quality of life and simplifying the complex regimen of diabetes management. As the prevalence of diabetes continues to rise globally, Insulet stands at the forefront of meeting a substantial medical need, capturing a significant market share with its user-friendly technology. As an investor, understanding Insulet’s growth trajectory and market potential is essential. The company has witnessed consistent revenue growth, driven by increased adoption of its Omnipod systems, and has expanded its product portfolio to include a new generation of devices that offer even greater functionality. Insulet is also heavily investing in research and development to further innovate its offerings, positioning itself competitively in the fast-evolving diabetes care market. With strong industry partnerships and a commitment to enhancing user experience, Insulet represents not just a promising investment in healthcare technology but also a company that is fundamentally improving the lives of millions.

PODD Intrinsic Value
99.02 USD
Overvaluation 64%
Intrinsic Value
Price

See Also

What is Insulet Corp's Accrued Liabilities?
Accrued Liabilities
423.9m USD

Based on the financial report for Sep 30, 2024, Insulet Corp's Accrued Liabilities amounts to 423.9m USD.

What is Insulet Corp's Accrued Liabilities growth rate?
Accrued Liabilities CAGR 10Y
33%

Over the last year, the Accrued Liabilities growth was 34%. The average annual Accrued Liabilities growth rates for Insulet Corp have been 46% over the past three years , 36% over the past five years , and 33% over the past ten years .

Back to Top